Search results
May 31, 2023 · Takeaway. Proton pump inhibitors (PPIs) reduce or inhibit the production of stomach acid, which relieves symptoms of acid reflux and gastroesophageal reflux disease (GERD). These medications are ...
Jun 11, 2022 · Any weight gain typically occurs mostly within the first 12 months of treatment. While weight gain is common, most women treated with aromatase inhibitors do not gain weight. One study reported that 39% of study participants had gained over 2 kg (4.4 lb), 27% had lost more than 2 kg, and 34% had stable weight after two years of endocrine ...
Jul 13, 2023 · Wind (flatulence). Headaches. Feeling sick (nausea). Tummy (abdominal) pain. Being sick (vomiting). A full list of side effects can be found in the leaflets that come with the medication. Recent studies have shown that people taking PPIs are at increased risk of gastric cancer (cancer of the stomach).
Feb 18, 2023 · Factor Xa inhibitors can: Lower your risk of stroke. Lower your risk of venous thrombosis (blood clots in your veins). Lower the risk of cardiovascular (heart and blood vessel) events in people with coronary artery disease and peripheral artery disease. Treat deep vein thrombosis (DVT).
Jun 1, 2017 · Key hypothalamic nuclei. The hypothalamus is one of the best-studied and most important brain regions involved in the central control of feeding and energy expenditure. In particular, the arcuate nucleus (ARC) within the hypothalamus is critical for the regulation of feeding and metabolism ( Myers and Olson, 2012 ).
Nov 21, 2022 · Proton pump inhibitors (PPIs) are medications used to treat gastroesophageal reflux disease (GERD). They work by lowering the amount of acid your stomach makes. Although rare, PPIs have been reported to cause weight gain. This may be more likely to happen with long-term use. But it hasn’t been clearly proven.
Cholinesterase inhibitors (ChEIs), also known as anti- cholinesterase, are chemicals that prevent the breakdown of the neurotransmitter acetylcholine or butyrylcholine. This increases the amount of the acetylcholine or butyrylcholine in the synaptic cleft that can bind to muscarinic receptors, nicotinic receptors and others.
